San Francisco, Oct. 29, 2016 – Recardio, announced that its scientific presentation on dutogliptin was accepted and will be presented by Darrell Nix, CSO, at the TCT conference in Washington.
The Transcatheter Cardiovascular Therapeutics (TCT) Conference will be held October 29 – November 2, 2016 at the Walter E. Washington Convention Center in Washington, DC.
Recardio’s poster presentation with the title “Impact of the novel DPP-IV-inhibitor dutogliptin in combination with G-CSF on survival rates and cardiac remodeling after acute myocardial infarction” will be presented by Darrell Nix on October 29 from 6:00 – 8:00 PM EDT.
All TCT abstracts will be published in a special JACC supplement that will be electronically available at the JACC website as well as TCTMD.com.
More information about the clinical program is available by visiting the following link.
Recardio is a clinical-stage life science company focusing on regenerative therapies for cardiovascular diseases. The company’s lead drug candidate, dutogliptin, is a DPP-IV inhibitor that has demonstrated significant effects in activating SDF-1, a protein that is critical for cardiac regeneration. The company has initiated a Phase 1/2 clinical program, seeking to fully develop the therapeutic platform as a regenerative medication for patients with various cardiovascular diseases including acute myocardial infarction and chronic heart failure, with the potential of improving heart function, quality of life and survival. For more information, visit: http://www.recardio.eu/